CClinicalTrials.gg
Sign In
RecruitingNCT06711861StreptobacilUpdated Dec 2, 2024

Multicenter Retrospective Study on Streptobacillus Moniliformis Infections in France

An observational study in Streptobacillus Moniliformis Infections, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by University Hospital, Strasbourg, France · Observational

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 7 months later.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
20
Ages
1 Year and older
Sex
All
01

Study summary

French data on Streptobacillus moniliformis infections (zoonosis transmitted by rat bites) are rare and there are no case series in the literature to date. This is a pathology presenting atypical clinical manifestations for a bacterial infection and which therefore remains underdiagnosed. Streptobacillus moniliformis infections can be fatal without appropriate antibiotic treatment. This study could improve diagnosis, develop early treatment strategies and contribute to the overall understanding of zoonotic diseases

02

Conditions studied

  • Streptobacillus Moniliformis Infections

Keywords

  • Streptobacillus moniliformis
  • Zoonosis
  • Rat bites
  • Zoonotic diseases
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's planned enrollment of 20 is below the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient having Streptobacillus moniliformis infection between 01/01/2007 and 31/12/2023

Inclusion criteria

  • Minor patient aged 1 to 17 years
  • Adult patient ≥18 years
  • Proven Streptobacillus moniliformis infection between 01/01/2007 and 31/12/2023
  • Subject not objecting, after being informed, to the reuse of their data for the purposes of this research
  • Holders of parental authority not objecting, after being informed, to the reuse of their data for the purposes of this research their child for the purposes of this research

Exclusion criteria

Exclusion Criteria:

  • Subject and/or holder of parental authority having expressed opposition to participating in the study
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
20 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Retrospective study of the effectiveness of antibiotic therapy initiated for the treatment of Streptobacillus moniliformis infection.

    Clinical cure 15 days after the start of antibiotic therapy. This cure is based on a negative blood culture (absence of germs) performed 15 days after the start of treatment.

    Time frame: Negative blood culture 15 days after the start of antibiotic therapy.

07

Study locations

1 of 1 sites recruiting
  • Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
    Strasbourg, 67091, France
    • François DANION, MD · Contact · francois.danion@chru-strasbourg.fr · 33 3 69 55 15 88
    • François DANION, MD · Principal investigator
    • Amandine ROBERT, MD · Principal investigator
    • Frédéric SCHRAMM, MD · Sub investigator
    • GUILLOUZOUIC GUILLOUZOUIC, PharmD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06711861
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Feb 16, 2024
Primary completion
Feb 16, 2025 (estimated)
Completion
Feb 16, 2025 (estimated)
Last update
Dec 2, 2024

Study contacts

François DANION, MD
Contact
francois.danion@chru-strasbourg.fr
33 3 69 55 15 88

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Infections→

Other studies from this sponsor

University Hospital, Strasbourg, France

Start the discussion